Curis (CRIS) AI Stock Analysis

• Market Cap: $21.00M
• Dividend Yield: N/A
• Average Volume (3M): 67.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.85
• Revenue Growth: 12.24%
• EPS Growth: 40.74%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 12,498,853
• 10 Day Avg. Volume: 78,658
• 30 Day Avg. Volume: 67,920
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.46
• Enterprise Value/Revenue: 4.53
• Enterprise Value/Gross Profit: 4.56
• Enterprise Value/Ebitda: -1.37
• 1Y Price Target: $14.50
• Price Target Upside: 763.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: $1.50 ▼(-10.71% Downside)

Curis' overall stock score is primarily impacted by its weak financial performance and valuation metrics. The company's ongoing financial challenges, including negative equity and cash flow issues, are significant concerns. Technical analysis also indicates bearish momentum. While there are positive developments in clinical trials, the limited cash runway and regulatory uncertainties add to the risk. The Nasdaq delisting notice further exacerbates the situation, highlighting the company's precarious market position.

Positive Factors

Clinical Development

The company remains focused on advancing its lead asset, emavusertib, a potential first-in-class oral, small molecule inhibitor of IRAK4, through clinical development.

Market Position

Emavusertib is the only IRAK4 inhibitor in late-stage clinical development, positioning it uniquely in a crowded market.

Regulatory Progress

Curis has received a positive regulatory foundation from both FDA and EMA, enhancing its potential market success.

Negative Factors

Clinical Trial Risks

Key risks include clinical trial failure, efficacy in limited patient types, and failure to expand the drug development pipeline.

Efficacy Data Expectations

In the AML program, safety studies aim to address any potential concerns associated with the triplet combination therapy, and meaningful efficacy data is not expected for at least 12 months.

Patient Enrollment Challenges

The primary challenge is the difficulty of enrollment, given the small patient population.

Curis Business Overview & Revenue Model

Company Description

Curis, Inc. (CRIS) is a biotechnology company focused on the development of innovative medicines for the treatment of cancer. The company operates primarily in the biopharmaceutical sector, specializing in targeted therapies and immunotherapies designed to address specific cancer pathways. Curis's core products include its proprietary drug candidates, which are in various stages of clinical development, aimed at providing new treatment options for patients with severe unmet medical needs in oncology.

How the Company Makes Money

Curis generates revenue primarily through the development and commercialization of its drug candidates. The company earns money through several key revenue streams, including milestone payments from partnerships with larger pharmaceutical companies, royalties on product sales, and potential licensing agreements for its proprietary technologies. Significant partnerships with larger biotech or pharmaceutical companies can provide upfront payments and additional funding contingent on the achievement of specific development milestones. Additionally, if any of Curis's products receive regulatory approval and reach the market, the company would benefit from sales revenue, contributing to its overall earnings.

Curis Financial Statement Overview

Summary

Curis faces significant financial challenges with persistent losses and negative cash flows. The balance sheet reveals negative stockholders' equity, indicating potential solvency issues. Despite some revenue growth, the company's profitability and balance sheet stability are concerning.

Income Statement

Curis shows a slight increase in revenue from the previous year, but the company still suffers from significant negative net income and EBIT margins, indicating ongoing profitability issues. The gross profit margin remains positive, but the net profit margin is deeply negative, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, which is concerning, indicating that liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity. This highlights potential solvency issues and financial instability.

Cash Flow

Curis has negative free cash flow and operating cash flow, which are troubling. The cash flow from operations is consistently negative, which may indicate difficulties in generating cash from core activities. Despite some improvement in cash flow from investing activities, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.40M	10.91M	10.02M	10.16M	10.65M	10.84M
Gross Profit	11.32M	10.81M	9.81M	9.90M	10.12M	10.30M
EBITDA	-37.56M	-42.57M	-45.14M	-50.51M	-39.98M	-24.67M
Net Income	-38.92M	-43.39M	-47.41M	-60.32M	-50.64M	-34.88M
Balance Sheet
Total Assets	29.23M	41.27M	77.28M	108.85M	162.30M	204.36M
Cash, Cash Equivalents and Short-Term Investments	10.14M	20.00M	56.33M	85.62M	139.85M	183.06M
Total Debt	32.47M	2.95M	2.79M	6.74M	5.04M	7.66M
Total Liabilities	43.22M	47.26M	57.61M	62.30M	71.59M	73.69M
Stockholders Equity	-13.99M	-6.00M	19.67M	46.55M	90.71M	130.67M
Cash Flow
Free Cash Flow	-30.46M	-39.56M	-38.43M	-54.75M	-37.62M	-26.42M
Operating Cash Flow	-30.46M	-39.56M	-38.43M	-54.34M	-37.62M	-25.74M
Investing Cash Flow	17.89M	29.44M	37.79M	33.02M	-47.90M	-49.05M
Financing Cash Flow	12.71M	3.44M	7.58M	867.00K	-4.17M	188.81M

Curis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 1.68 is above the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.77, and below the 200-day MA of 2.52, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 44.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.

Curis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PULM	53 Neutral	$17.79M	―	-83.85%	―	-96.76%	26.87%
Sector *	51 Neutral	$7.95B	-0.40	-41.62%	2.21%	22.29%	-1.85%
MBRX	44 Neutral	$11.36M	―	-503.80%	―	―	60.64%
CRIS	42 Neutral	$21.00M	―	-2951.24%	―	12.24%	40.74%
CYCC	38 Underperform	$15.94M	―	-276.72%	2.11%	-87.50%	92.82%
RLYB	35 Underperform	$25.43M	―	-66.12%	―	154.52%	47.84%
ELEV	33 Underperform		―		―	―	47.73%

Curis Corporate Events

Curis Appeals Nasdaq Delisting Notice After Non-Compliance

On February 21, 2025, Curis, Inc. was notified by Nasdaq that it was not in compliance with the market value listing standard, as its securities’ market value had been below $35 million for 30 consecutive trading days. Despite a 180-day compliance period ending on August 20, 2025, Curis failed to meet the requirement and was informed on August 21, 2025, that its securities would be delisted unless it appealed the decision. Curis intends to request a hearing to appeal, which will temporarily halt the delisting process, but there is no guarantee of regaining compliance.

Curis Files Prospectus Supplement for Stock Offering

On August 8, 2025, Curis, Inc. announced the filing of a prospectus supplement under its universal shelf registration statement with the SEC, allowing for the offer and sale of up to $8,137,047 of common stock. This move follows the company’s decision on July 1, 2025, to terminate a prior prospectus related to a larger offering, while maintaining the existing sales agreement with Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC. The legal opinion regarding the shares was provided by Wilmer Cutler Pickering Hale and Dorr LLP.

Curis Announces $7M Securities Purchase Agreement

On July 2, 2025, Curis, Inc. announced a securities purchase agreement with institutional investors to raise approximately $7 million through a combination of registered direct offerings and private placements. This financial move is expected to support the company’s operations into the first quarter of 2026, providing a cash runway to advance its research and development programs. The agreement includes the issuance of common stock and warrants, with the offerings anticipated to close by July 3, 2025, subject to customary conditions. The company has engaged Laidlaw & Company and JonesTrading Institutional Services as co-placement agents for the transaction.